Target intelligence / Profile preview

Peptidyl-prolyl cis-trans isomerase F, mitochondrial (Cyclophilin D) (CypD)

Target
CypD
Molecular classification
Enzyme, Peptidyl-prolyl cis-trans isomerase, Immunophilin
01

Overview

Cyclophilin D (CypD), encoded by the PPIF gene, is a peptidyl-prolyl cis-trans isomerase located within the mitochondrial matrix (UniProt P30405). It serves as a key regulatory component of the mitochondrial permeability transition pore (mPTP), a high-conductance channel in the inner mitochondrial membrane (PubMed: 15744310). Under physiological conditions, CypD helps maintain mitochondrial function, but during pathological stress—such as oxidative stress or calcium overload—it triggers the opening of the mPTP. This opening leads to mitochondrial swelling, loss of membrane potential, and the release of pro-apoptotic factors, ultimately resulting in cell death via necrosis or apoptosis (PubMed: 15744311). Consequently, CypD is a significant therapeutic target for diseases characterized by mitochondrial dysfunction, including myocardial ischemia-reperfusion injury, stroke, and neurodegenerative conditions like Alzheimer's and Parkinson's diseases (PubMed: 25648232). Drugs like Cyclosporine A and its non-immunosuppressive analogs, such as Alisporivir, target CypD to prevent mPTP opening and protect cells from injury (PubMed: 21854169).

Other names
PPIFCyclophilin FMitochondrial cyclophilinRotamase FCyclophilin 18Cyp-F
02

Mechanism of action

Inhibition of the peptidyl-prolyl isomerase activity of Cyclophilin D, which prevents its interaction with the mitochondrial permeability transition pore (mPTP) complex, thereby inhibiting pore opening and subsequent cell death (PubMed: 15744310).

03

Biological functions

Mitochondrial permeability transition pore regulationProtein foldingApoptosisNecrosisCalcium homeostasisMitochondrial bioenergetics
04

Disease associations

Ischemia-reperfusion injuryNeurodegenerative diseaseMuscular dystrophyCardiovascular diseaseAcute pancreatitisAlzheimer's diseaseMultiple sclerosis
05

Safety considerations

Immunosuppression (when using non-selective inhibitors like Cyclosporine A that also target Cyclophilin A and calcineurin)Potential disruption of normal mitochondrial bioenergeticsOff-target effects on other cyclophilin isoforms (PubMed: 21854169)
06

Interacting drugs

Cyclosporine A

3 more in the full profile.

07

Biomarkers

Mitochondrial membrane potential (Delta-Psi-m)Cytochrome c releaseLactate dehydrogenase (LDH) levelsMitochondrial swelling

Beyond the preview

Go deeper on Peptidyl-prolyl cis-trans isomerase F, mitochondrial (Cyclophilin D) (CypD).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peptidyl-prolyl cis-trans isomerase F, mitochondrial (Cyclophilin D) (CypD).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call